Accordingly, it was found, for the first time, that α1,3fucosylated AGP could be an appropriate marker of disease progression and prognosis in various cancer patients, and that abnormally high levels of FUCAGP were found in patients with esophagus, stomach, lung, breast, liver, pancreas, colon and rectum carcinomas who had a poor prognosis25,26. The gene discussed is ATP5MK; the disease is cancer.